MYGN Stock Analysis: Buy, Sell, or Hold?
MYGN - Myriad Genetics Inc
$3.02
0.16 (5.59%)
β²
5d:
-44.59%
30d:
-49.58%
90d:
-37.08%
WAIT
LOW Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When MYGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
βΈοΈ WAIT FOR STABILIZATION: MYGN is down 44.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
βΈοΈ WAIT FOR STABILIZATION: MYGN is down 44.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MYGN is currently trading at $3.02, which is considered oversold relative to its 30-day fair value range of $4.79 to $6.40. From a valuation perspective, the stock is trading at a discount (Forward PE: -45.3) compared to its historical average (50.8). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MYGN is in a uptrend. Immediate support is located at $2.74, while resistance sits at $5.99. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.75 (+90.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MYGN is in a uptrend. Immediate support is located at $2.74, while resistance sits at $5.99. The stock is showing strong short-term momentum, up 5.6% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.75 (+90.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.79 -
$6.40
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.0%
Protect Your Profits
Holding MYGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.6%)
- BULLISH: Trading 90.4% below Wall St target ($5.75)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to -44.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.79 -
$6.40
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.74
Resistance Level
$5.99
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-45.28
Wall Street Target
$5.75
(+90.4%)
Revenue Growth (YoY)
-20.8%
Profit Margin
-41.3%
PE vs Historical
-45.3 vs 50.8
CHEAP
Share & Embed Analysis
Last updated: August 04, 2026 6:39 AM ET
Data refreshes hourly during market hours. Next update: 7:39 AM
Data refreshes hourly during market hours. Next update: 7:39 AM
π₯ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MYGN showing a specific setup today?
Insider Activity (6 Months)
4
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Samraat S Raha
BUY
40000 shares
2026-03-09
S. Louise Phanstiel
BUY
48000 shares
2026-02-27
S. Louise Phanstiel
BUY
50407 shares
2026-02-26
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific⦠|
STRONG BUY
31 analysts |
$630 | 57 HOLD |
|
EXAS
EXACT Sciences Corporati⦠|
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$188 | 57 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$228 | 54 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$283 | 56 HOLD |
Advanced MYGN Option Strategies
Professional options setups generated by AI based on today's MYGN price and gamma walls.